ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation

5/5 In Vitro

Konduri et al., bioRxiv, doi:10.1101/2021.05.05.442779 (Preprint) (In Vitro)
ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation

Source PDF Share Tweet

In Vitro study and animal study showing that ProLung™-budesonide inhibits SARS-CoV-2 replication (results for budesonide were not provided). ProLung™-budesonide and budesonide significantly decreased lung inflammation. ProLung™-budesonide is a formulation for sustained administration of a low dose of budesonide using a vehicle similar to lung surfactant.

Konduri et al., 5/5/2021, preprint, 10 authors.

All 4 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit